Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

BOLT

Bolt Biotherapeutics (BOLT)

Bolt Biotherapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:BOLT
DateTimeSourceHeadlineSymbolCompany
07/12/20245:10PMPR Newswire (US)BOLT SHAREHOLDER ALERT: Edelson Lechtzin LLP Urges Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) Shareholders to Consult Legal Counsel About the Pending Securities Fraud Class ActionNASDAQ:BOLTBolt Biotherapeutics Inc
06/14/20246:54PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BOLTBolt Biotherapeutics Inc
06/14/20246:45PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BOLTBolt Biotherapeutics Inc
06/14/20241:15PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:BOLTBolt Biotherapeutics Inc
05/20/20241:22PMEdgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:BOLTBolt Biotherapeutics Inc
05/15/20245:43PMEdgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:BOLTBolt Biotherapeutics Inc
05/14/20244:14PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:BOLTBolt Biotherapeutics Inc
05/14/20244:06PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:BOLTBolt Biotherapeutics Inc
05/14/20244:05PMGlobeNewswire Inc.Bolt Biotherapeutics Reports First Quarter 2024 Results, Announces Strategic Pipeline Prioritization and Changes to Leadership TeamNASDAQ:BOLTBolt Biotherapeutics Inc
03/21/20244:05PMGlobeNewswire Inc.Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business UpdateNASDAQ:BOLTBolt Biotherapeutics Inc
03/06/20241:29PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BOLTBolt Biotherapeutics Inc
03/06/20241:27PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BOLTBolt Biotherapeutics Inc
02/27/20247:00AMGlobeNewswire Inc.Bolt Biotherapeutics to Present at the TD Cowen 44th Annual Healthcare ConferenceNASDAQ:BOLTBolt Biotherapeutics Inc
02/12/20249:41PMEdgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:BOLTBolt Biotherapeutics Inc
02/06/20241:09PMEdgar (US Regulatory)Form 5 - Annual statement of changes in beneficial ownership of securitiesNASDAQ:BOLTBolt Biotherapeutics Inc
12/21/20237:30AMGlobeNewswire Inc.Pacira Appoints Frank D. Lee as Chief Executive OfficerNASDAQ:BOLTBolt Biotherapeutics Inc
12/13/20231:40PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BOLTBolt Biotherapeutics Inc
12/05/20237:00AMGlobeNewswire Inc.Bolt Biotherapeutics Enrolls First Patient in Phase 2 Clinical Study Evaluating BDC-1001 in Patients with HER2-Positive Breast Cancer Previously Treated with Enhertu®NASDAQ:BOLTBolt Biotherapeutics Inc
11/09/20234:10PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:BOLTBolt Biotherapeutics Inc
11/09/20234:08PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:BOLTBolt Biotherapeutics Inc
11/09/20234:05PMGlobeNewswire Inc.Bolt Biotherapeutics Reports Third Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:BOLTBolt Biotherapeutics Inc
11/07/20237:00AMGlobeNewswire Inc.Bolt Biotherapeutics to Present at Stifel 2023 Healthcare ConferenceNASDAQ:BOLTBolt Biotherapeutics Inc
10/23/202310:30AMGlobeNewswire Inc.Bolt Biotherapeutics Presents Updated Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 as Monotherapy and in Combination with Nivolumab in HER2-Expressing Tumors at ESMO 2023 CongressNASDAQ:BOLTBolt Biotherapeutics Inc
10/18/20237:00AMGlobeNewswire Inc.Bolt Biotherapeutics to Present Data at the Society for Immunotherapy of Cancer’s 2023 Annual MeetingNASDAQ:BOLTBolt Biotherapeutics Inc
10/17/20237:00AMGlobeNewswire Inc.Bolt Biotherapeutics Announces First Patient Dosed in Phase 1/2 Study of BDC-3042 in Patients with Advanced CancersNASDAQ:BOLTBolt Biotherapeutics Inc
10/16/20237:00AMGlobeNewswire Inc.Bolt Biotherapeutics to Present New Clinical Data from Completed Phase 1/2 Dose-Escalation Trial of BDC-1001 in HER2-Expressing Solid Tumors at the ESMO Congress 2023NASDAQ:BOLTBolt Biotherapeutics Inc
09/28/20237:00AMGlobeNewswire Inc.Bolt Biotherapeutics Receives Orphan Drug Designation for BDC-1001 for Treatment of Gastric CancersNASDAQ:BOLTBolt Biotherapeutics Inc
09/12/20238:05AMGlobeNewswire Inc.Bolt Biotherapeutics Announces Issuance of U.S. Patent Covering Dectin-2-Targeting Agonist Antibodies, Including BDC-3042NASDAQ:BOLTBolt Biotherapeutics Inc
09/05/20234:15PMGlobeNewswire Inc.Bolt Biotherapeutics to Participate in September Investor ConferencesNASDAQ:BOLTBolt Biotherapeutics Inc
08/07/20234:10PMGlobeNewswire Inc.Bolt Biotherapeutics Reports Second Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:BOLTBolt Biotherapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:BOLT